You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
開拓藥業-B(09939.HK):減少普克魯胺用於治療新冠臨床試驗開支
阿思達克 03-29 09:34
開拓藥業-B(09939.HK)在認購事項所籌得的所得款項淨額約為5.09億元,公司建議更改對尚未動用的所得款項的用途重新分配。 公司表示,考慮到公司現時財務狀況,決定減少普克魯胺用於治療新冠臨床試驗的開支。同時,公司將分配約15%的資金用於普克魯胺,主要由於向第三方支付未付款項;約49%的資金將被用於公司於內地及全球推進的其他處於臨床階段的候選化合物臨床試驗,包括福瑞他恩以及AR-PROTAC化合物GT20029。 至於其餘資金將作為公司營運資金,以加強研發和業務拓展團隊的建設,進而提升公司的研發和商業化水平。(ca/u) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account